Jan 02, 2020 / 10:00PM GMT
Operator
Greetings, and welcome to the Incyte GRAVITAS-301 Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to introduce your host, Mike Booth, Head of Investor Relations for Incyte. Please go ahead, sir.
Michael Booth - Incyte Corporation - Divisional VP of IR & Corporate Social Responsibility
Thank you, Kevin. Good afternoon, and welcome to Incyte's conference call to discuss the results of the Phase III GRAVITAS-301 trial of Incyte's itacitinib for patients with steroid-naive acute graft-versus-host disease. This conference call is being recorded and is also being broadcast as an audio-only webcast.
I'm joined on the call today by Hervé, Steven and Christiana as well as by Peter Langmuir from our clinical development group. Peter leads all of our GVHD clinical development efforts, including the REACH and GRAVITAS programs. Hervé and Peter will make some introductory remarks before we move to Q&A, during which I ask that you limit yourself to 1 question, and if needed, 1
Incyte Corp GRAVITAS-301 Call Transcript
Jan 03, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers